Estuary Biotherapeutics launches with $103 million for polycystic kidney disease gene therapies
Start here
Estuary Biotherapeutics, a California genetic medicines company founded in 2022 on Yale research by Stefan Somlo and Michael Caplan, has emerged from stealth with $103 million in financing to advance gene therapies for autosomal dominant polycystic kidney disease (ADPKD). The total includes a $93 million Series A led by RA Capital Management and a $10 million seed from 4BIO Capital and GV, with Deep Track Capital also participating. Its two AAV-delivered leads, EST-101 and a full-length PKD2 program, EST-201, aim to restore polycystin function. EST-201 is expected to enter the clinic in 2027 in PKD2-mutation ADPKD patients, followed by EST-101 in 2028. ADPKD affects roughly 1 in 400 to 1,000 people, and tolvaptan is the only approved drug.
Written by a model from the reports · updated 2 min ago
Coverage timeline
Follow the coverage to see the different angles.
- biospace.comPickEstuary sails into kidney disease space with $103M for gene therapies
Estuary Biotherapeutics emerged from stealth with $103 million in financing for two lead gene therapies targeting autosomal dominant polycystic kidney disease (ADPKD). The total comprises a $93 million series A led by RA Capital Management and a $10 million seed from 4BIO Capital and GV. EST-201, a full-length PKD2 gene therapy delivered via AAV, enters the clinic in 2027 in PKD2-mutation ADPKD patients, while AAV-delivered EST-101 is expected to enter the clinic in 2028.
- biopharmadive.comBiogen-backed Estuary nabs $93M for kidney disease gene therapy
Estuary Biotherapeutics, a California genetic medicines developer founded in 2022 around Yale research by Stefan Somlo and Michael Caplan, has launched with a $93 million Series A led by RA Capital Management, with participation from Deep Track Capital, 4BIO Capital and Alphabet's GV. Its lead gene therapy programs, EST-201 and EST-101, target autosomal dominant polycystic kidney disease by restoring polycystin function, with human testing expected in 2027 and 2028. Only one drug, tolvaptan, is currently approved for ADPKD, which affects roughly 1 in 400 to 1,000 people.
Heat trend for this story
Heat now 19·Peak in the comparable set 19 (Oct 16 22:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.